BioSpace News Archive

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its second quarter 2023 results before the market opens on Tuesday, August 1, 2023, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Biotheus Inc. (“Biotheus”) announced today that it has entered into a strategic research collaboration, option and worldwide license agreement with BioNTech SE (“BioNTech”), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.

BioArctic AB’s partner Eisai announced that the results of a detailed analysis of the Phase 3 Clarity AD study, presented at the Alzheimer’s Association International Conference 2023, demonstrated that lecanemab-irmb treatment showed benefits on both amyloid-beta and tau pathology as well as other downstream biomarker changes.

Cerapedics Inc. announced it is expanding its headquarters in the Denver metro area to support the growth of its products, which include the U.S. Food and Drug Administration -approved i-FACTOR® bone graft for cervical spinal fusion and its next-generation product currently being evaluated for lumbar spinal fusion.

Rapid Medical™, a leading developer of advanced neurovascular devices, today announced new clinical data showing significant advantages of its novel COMANECI™ embolization assist device over established techniques to treat ruptured wide-neck intracranial aneurysms.

On behalf of the 37 million adults in America with kidney diseases, including the over 90 percent who are unaware that they have chronic kidney disease, the American Society of Nephrology and the National Kidney Foundation express our concern that the United States Preventive Services Task Force Final Research Agenda for chronic kidney disease screening continues to focus on screening only of asymptomatic, low-risk individuals.

Padagis, a leading provider of extended topical and other specialty pharmaceuticals, announced today the approval of its over-the-counter (OTC) labeling supplement for naloxone hydrochloride nasal spray (therapeutically equivalent to Narcan® nasal spray).

Immunovia, the diagnostics company focused on early detection of pancreatic cancer, updates its financial calendar for 2023.

Why do nonsteroidal anti-inflammatory drugs exacerbate gastrointestinal infections by Clostridioides difficile, the leading cause of antibiotic-associated diarrhea worldwide? In a new paper published in Science Advances, researchers at Children’s Hospital of Philadelphia have begun to answer that question, showing that NSAIDs disrupt the mitochondria of cells lining the colon, sensitizing them to damage by pathogenic toxins.

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has followed guidance provided by the Committee for Medicinal Products for Human Use (CHMP) in May this year, and has not granted marketing authorization for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (FOP).